Recently Released Market Study: Caldera Health Limited - Product Pipeline Analysis
Caldera Health Limited (Caldera) develops diagnostic devices for the detection of early stage prostate cancer. Its portducts include ProscaNZ, a blood test for prostate cancer, that extends the diagnostic range and accuracy of the current PSA test; ProstScreen, a gene-based device to distinguish between indolent and rapidly progressive cancers and undertake treatment by use of urine samples, plasma, circulating tumour cells or biopsy tissues; and MonitorChip, that monitors the efficacy and optimum duration of specific therapies by analysing proteins in...
View full press release